Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

JAMA Study Links Plasma eMTBR-Tau to Advanced CTE in 21 Former Football Players

A Boston University-led JAMA study of 21 brain donors found higher plasma eMTBR-tau in advanced CTE; authors say larger validation is needed.

Published 19 Nov 2026· 7 minute read
A researcher in a laboratory examines a blood sample, the kind of plasma analysis used in biomarker studies
Photo: National Eye Institute / Wikimedia Commons, CC BY 2.0 (cropped). Source · Licence

On 19 November 2026, a Boston University-led team reported in JAMA that a blood measure called plasma eMTBR-tau was higher in former American football players whose brains later showed advanced chronic traumatic encephalopathy (CTE) at autopsy. The study covers only 21 brain donors, and the authors say larger autopsy studies must confirm it before any clinical use.

What happened

The paper, “Plasma eMTBR-Tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology” (DOI 10.1001/jama.2026.24780), appeared online in JAMA as an Original Investigation. Michael Alosco, co-director of clinical research at the BU CTE Center, is the corresponding author. The authors also include Thor Stein, Ann McKee, Jesse Mez, Henrik Zetterberg and Nicholas Ashton. Boston University’s own account says the work was led by BU and Banner Health.

The team analysed blood plasma drawn during life from 21 men who had played American-style football and who later donated their brains to the BU CTE Center Brain Bank. The JAMA paper describes the design as a case series. The authors measured eMTBR-tau, short for endogenously cleaved microtubule-binding region tau, and compared it with the neuropathology found after death. Autopsy review was completed by 9 October 2026.

Of the 21 donors, 18 had CTE at autopsy and 3 did not. Sixteen of the 18 had high-stage disease (stage III or IV) and 2 had low-stage disease (stage I or II). Five of the CTE cases also had intermediate or high Alzheimer’s disease neuropathologic change. According to the ESPN report carried by TSN, 12 of the donors played professionally, 7 played in college and 2 played only in high school.

Key details

The paper reports that median plasma eMTBR-tau was 0.019 pg/mL in donors with CTE and 0.001 pg/mL in donors without it (β = 1.61, 95% confidence interval 0.51 to 2.70, on log-transformed concentrations). Donors with high-stage CTE had a median of 0.021 pg/mL, against 0.001 pg/mL for both low-stage and no-CTE donors. The difference between high-stage CTE and no CTE stayed significant when the five donors with Alzheimer’s pathology were excluded.

Group in the JAMA case series Median plasma eMTBR-tau (pg/mL)
CTE at autopsy (n = 18) 0.019
No CTE (n = 3) 0.001
High-stage CTE (n = 16) 0.021
Low-stage CTE (n = 2) 0.001
CTE with Alzheimer’s neuropathology 0.082
High-stage CTE without Alzheimer’s neuropathology 0.009

The Boston University article says p-tau217, a blood marker already studied in Alzheimer’s disease, was elevated only in participants with Alzheimer’s disease and not in CTE alone. Alosco told BU that a combination of eMTBR-tau and p-tau217 “might be optimal” for detecting CTE during life and telling it apart from Alzheimer’s disease. The authors report no sensitivity, specificity or diagnostic-accuracy figures, so the study does not show how well the measure would identify CTE in an individual.

BU states that the study was supported by funding from the National Institute of Neurological Disorders and Stroke and the National Institute on Aging.

Background and context

CTE is a neurodegenerative disease linked to repeated head impacts, and it can currently be confirmed only by examining the brain after death. The BU CTE Center has been working toward a diagnosis during life. In 2025 the university announced a $15 million NIH award for a BU-led effort to diagnose CTE in living people with blood biomarkers and brain imaging, as described in a BU announcement; the blood draws from several of the 21 donors came from earlier studies in that programme.

A second JAMA paper on the same blood measure appeared on 16 November 2026. Brum and colleagues, led from Banner Sun Health Research Institute with Washington University School of Medicine among the contributing institutions, reported “A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology” (DOI 10.1001/jama.2026.25143). That study of 728 participants in four cohorts looked at Alzheimer’s-type tau pathology rather than CTE. It found the immunoassay separated advanced from earlier tau stages at autopsy, with an area under the curve of 0.93 for eMTBR-tau against 0.84 for p-tau217 in one autopsy cohort. TSN’s report describes the two papers together as showing potential for detecting CTE in the living.

Reaction

Alosco called the result a “game changer” in an interview with CBS Boston. In the same coverage, the researchers stressed that the test is not approved by the US Food and Drug Administration, is not available to the public and should not be used to diagnose CTE now. Alosco also described the study to BU as a small sample that is nonetheless “the gold standard type of study design” for identifying a biomarker, adding “we aren’t there yet.”

WBUR reported that the authors caution that more research is needed to verify the results, and that the measure showed promise for advanced-stage CTE rather than for early disease. TSN reached the same conclusion, noting the measure did not identify early-stage CTE.

What it means for researchers, universities and research offices

For neurology and neuropathology groups, the study is a discovery-phase signal: 21 donors, a convenience sample drawn from several BU studies, mostly men with advanced disease, and a median age at blood draw of 68 years in the CTE group against 49 in the three donors without CTE. Anyone planning a replication will need larger autopsy-confirmed series with more low-stage cases and a comparison group with Alzheimer’s disease but no CTE, which the paper’s limitations identify as gaps.

For research offices and institutional review boards, the work illustrates a recurring set of obligations in brain-donation research: consent that links antemortem blood collection to later brain donation, long-term biobank stewardship, and clear participant communication that a research biomarker result is not a clinical diagnosis. Programmes that return or discuss biomarker findings with former athletes or families should state plainly that no approved test exists.

For laboratories and core facilities, the immunoassay described in the companion paper used antibodies supplied by Bioventix, so any lab planning to run the measure should check reagent access and assay validation before building a protocol. Teams already working on brain-injury markers can compare it with established candidates such as the GFAP protein, and those writing up small case series should note the reporting differences between a case series and a case report. Journal editors and reviewers will also see this paper in the context of JAMA-family neurology publishing.

For funders, the evidence base is a pair of NIH-supported lines of work, with NINDS and NIA named for the BU paper; the Banner-led paper lists support from Lund University’s MultiPark programme, NIH, the Alzheimer’s Association and Swedish and Canadian sources. Larger validation studies of the kind the authors call for would require multi-site brain banks and standardised assays.

What happens next

Alosco told WBUR that a blood test could move toward FDA approval within about five years if larger studies confirm the findings, and TSN quotes him as cautiously optimistic on that timeline. The next steps the researchers describe are validation in larger autopsy studies, work to relate the measure to symptoms and brain changes, and a bigger sample. No date has been announced for those studies.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →